LOADING
Comparing Johnson & Johnson (JNJ) and AbbVie Inc (ABBV), both in the Health Care sector. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | JNJ | ABBV |
|---|---|---|
| Price | $253.85 | $244.78 |
| Change Today | -1.52% | -1.30% |
| Market Cap | $618.6B | $438.3B |
| P/E Ratio | 29.8 | 122.2 |
| Forward P/E | 22.2 | 17.4 |
| PEG Ratio | 4.94 | 0.40 |
| EPS | $8.63 | $2.03 |
| Revenue Growth (YoY) | 9.9% | 12.4% |
| Profit Margin | 21.8% | 5.8% |
| Return on Equity | 26.4% | 62.3% |
| Dividend Yield | 2.01% | 2.70% |
| Beta | 0.23 | 0.28 |
| 52-Week High | $269.43 | $261.64 |
| 52-Week Low | $155.89 | $180.35 |
| Volume | 8.8M | 5.2M |
Johnson & Johnson is the larger company by market capitalization. Johnson & Johnson trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. AbbVie Inc offers a higher dividend yield for income investors. Johnson & Johnson has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.